Differential expression of the nuclear receptors farnesoid X receptor (FXR) and pregnane X receptor (PXR) for grading dysplasia in patients with Barrett's oesophagus

Histopathology

Volumn 58, Issue 2, 2011, Pages 246-253

  Van De Winkel, Anouk ^a   Van Zoest, Katinka P M ^a   Van Dekken, Herman ^a   Moons, Leon M G ^a   Kuipers, Ernst J ^a   Van Der Laan, Luc J W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Barrett's oesophagus; Biomarker; Dysplasia; Farnesoid X receptor; Immunohistochemistry; Oesophageal adenocarcinoma; Pregnane X receptor

Indexed keywords

FARNESOID X RECEPTOR; PREGNANE X RECEPTOR;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; DYSPLASIA; ESOPHAGUS BIOPSY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BARRETT ESOPHAGUS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; METAPLASIA; MIDDLE AGED; PRECANCEROUS CONDITIONS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 79951595623     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03743.x     Document Type: Article

References (46)

1. Jankowski JA, Harrison RF, Perry I, Balkwill F, Tselepis C. Barrett's metaplasia. Lancet 2000; 356; 2079-2085.
2. Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum. Pathol. 1994; 25; 982-993.
3. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am. J. Gastroenterol. 2008; 103; 788-797.
4. Falk GW. Barrett's esophagus. Gastroenterology 2002; 122; 1569-1591.
5. Falk GW. Barrett's esophagus-is it bad for your health? Am. J. Gastroenterol. 2005; 100; 2622-2623.
6. van Soest EM, Dieleman JP, Siersema PD, Sturkenboom MC, Kuipers EJ. Increasing incidence of Barrett's oesophagus in the general population. Gut 2005; 54; 1062-1066.
7. Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993; 104; 510-513.
8. Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96; 1249-1256.
9. Cameron AJ, Carpenter HA. Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study. Am. J. Gastroenterol. 1997; 92; 586-591.
10. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8years. Am. J. Gastroenterol. 1997; 92; 212-215.
11. Hage M, Siersema PD, van Dekken H, Steyerberg EW, Dees J, Kuipers EJ. Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7years. Scand. J. Gastroenterol. 2004; 39; 1175-1179.
12. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002; 122; 633-640.
13. Streitz JM Jr, Andrews CW Jr, Ellis FH Jr. Endoscopic surveillance of Barrett's esophagus. Does it help? J. Thorac. Cardiovasc. Surg. 1993; 105; 383-387; discussion 387-388;
14. Schlemper RJ, Riddell RH, Kato Y et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47; 251-255.
15. di Pietro M, Peters CJ, Fitzgerald RC. Clinical puzzle: Barrett's oesophagus. Dis. Model Mech. 2008; 1; 26-31.
16. Sharma P, Sidorenko EI. Are screening and surveillance for Barrett's oesophagus really worthwhile? Gut 2005; 54(Suppl. 1); i27-i32.
17. Buttar NS, Wang KK, Lutzke LS, Krishnadath KK, Anderson MA. Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett's esophagus. Gastrointest. Endosc. 2001; 54; 682-688.
18. Weston AP, Sharma P, Topalovski M, Richards R, Cherian R, Dixon A. Long-term follow-up of Barrett's high-grade dysplasia. Am. J. Gastroenterol. 2000; 95; 1888-1893.
19. Montgomery E, Goldblum JR, Greenson JK et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum. Pathol. 2001; 32; 379-388.
20. Burke AP, Sobin LH, Shekitka KM, Helwig EB. Dysplasia of the stomach and Barrett esophagus: a follow-up study. Mod. Pathol. 1991; 4; 336-341.
21. Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin. Gastroenterol. Hepatol. 2006; 4; 566-572.
22. Conio M, Blanchi S, Lapertosa G et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am. J. Gastroenterol. 2003; 98; 1931-1939.
23. Dulai GS, Shekelle PG, Jensen DM et al. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort. Am. J. Gastroenterol. 2005; 100; 775-783.
24. Skacel M, Petras RE, Gramlich TL, Sigel JE, Richter JE, Goldblum JR. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am. J. Gastroenterol. 2000; 95; 3383-3387.
25. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am. J. Gastroenterol. 2000; 95; 1669-1676.
26. Kerkhof M, van Dekken H, Steyerberg EW et al. Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology 2007; 50; 920-927.
27. Montgomery E, Bronner MP, Goldblum JR et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum. Pathol. 2001; 32; 368-378.
28. Sharma P. Low-grade dysplasia in Barrett's esophagus. Gastroenterology 2004; 127; 1233-1238.
29. Kerkhof M, Kusters JG, van Dekken H, Kuipers EJ, Siersema PD. Biomarkers for risk stratification of neoplastic progression in Barrett esophagus. Cell Oncol. 2007; 29; 507-517.
30. van Dekken H, Hop WC, Tilanus HW et al. Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus. Am. J. Clin. Pathol. 2008; 130; 745-753.
31. Krishnadath KK, Tilanus HW, van Blankenstein M et al. Accumulation of genetic abnormalities during neoplastic progression in Barrett's esophagus. Cancer Res. 1995; 55; 1971-1976.
32. Schulmann K, Sterian A, Berki A et al. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 2005; 24; 4138-4148.
33. Gray MR, Hall PA, Nash J, Ansari B, Lane DP, Kingsnorth AN. Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization. Gastroenterology 1992; 103; 1769-1776.
34. Zollner G, Marschall HU, Wagner M, Trauner M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol. Pharm. 2006; 3; 231-251.
35. Makishima M, Okamoto AY, Repa JJ et al. Identification of a nuclear receptor for bile acids. Science 1999; 284; 1362-1365.
36. Kliewer SA, Moore JT, Wade L et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998; 92; 73-82.
37. Zhang F, Altorki NK, Wu YC, Soslow RA, Subbaramaiah K, Dannenberg AJ. Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids. Gastroenterology 2001; 121; 1391-1399.
38. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 1998; 102; 1016-1023.
39. Bertilsson G, Heidrich J, Svensson K et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc. Natl Acad. Sci. USA 1998; 95; 12208-12213.
40. Blumberg B, Sabbagh W Jr, Juguilon H et al. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev. 1998; 12; 3195-3205.
41. Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu. Rev. Cell Dev. Biol. 2000; 16; 459-481.
42. De Gottardi A, Touri F, Maurer CA et al. The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. Dig. Dis. Sci. 2004; 49; 982-989.
43. De Gottardi A, Dumonceau JM, Bruttin F et al. Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro. Mol. Cancer 2006; 5; 48.
44. Capello A, Moons LM, Van de Winkel A et al. Bile acid-stimulated expression of the farnesoid X receptor enhances the immune response in Barrett esophagus. Am. J. Gastroenterol. 2008; 103; 1510-1516.
45. Sikkema M, Kerkhof M, Steyerberg EW et al. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study. Am. J. Gastroenterol. 2009; 104; 2673-2680.
46. Jin Z, Cheng Y, Gu W et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res. 2009; 69; 4112-4115.